Do Diabetic Foot Infections With Methicillin-Resistant Staphylococcus aureus Differ From Those With Other Pathogens?

被引:53
|
作者
Zenelaj, Besa [1 ,2 ]
Bouvet, Cindy [1 ,2 ]
Lipsky, Benjamin A. [1 ,2 ,3 ]
Uckay, Ilker [1 ,2 ]
机构
[1] Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland
[2] Fac Med, Geneva, Switzerland
[3] Univ Oxford, Oxford, England
来源
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS | 2014年 / 13卷 / 04期
关键词
diabetic foot infection; Staphylococcus aureus; MRSA; review; treatment; RISK-FACTORS; SOFT-TISSUE; MICROBIAL PROFILE; CLINICAL-OUTCOMES; TREATMENT FAILURE; COMPLICATED SKIN; ULCERS; VANCOMYCIN; OSTEOMYELITIS; PREVALENCE;
D O I
10.1177/1534734614550311
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
There is controversy as to whether or not diabetic foot infections (DFIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) are associated with worse outcomes than DFIs caused by other pathogens. To address this issue we performed a nonsystematic literature search of published articles in English language journals seeking studies reporting on the outcomes of DFIs related to their microbiology. We retrieved 48 articles published from 1999 to 2013 that described a total of 7771 cases of DFI. The overall proportion of DFIs with an isolate of S aureus was about 30%; just over one third of these (11% of all cases) were MRSA strains. Among the DFI cases caused by MRSA 1543 were episodes of soft tissue infections and 113 of osteomyelitis, while non-MRSA organisms caused 5761 soft tissue infections and 354 cases of osteomyelitis. Only 5 of the included articles attempted a comparison between DFI caused by MRSA and those caused by other pathogens, with no clear differences noted. The median total duration of antibiotic therapy for DFI caused by MRSA was 26 days, of which a median of 10 days was given intravenously. Only a few articles reported the proportion of patients with a recurrence, but they often did not differentiate between MRSA and non-MRSA cases. Four publications reported a worse functional or microbiological outcome in MRSA, compared to non-MRSA, cases, but the findings were variable and differences did not seem to be significant. Many trials failed to adjust for case-mix or to definitively demonstrate a relationship between microbiology and outcomes. Few of the articles specifically commented on whether the MRSA isolates were health care- or community-acquired strains. Notwithstanding the substantial limitations of the available literature, there does not appear to be a need for any special treatment for DFI caused by MRSA. The current guidelines for treating according to established international recommendations seem appropriate.
引用
收藏
页码:263 / 272
页数:10
相关论文
共 50 条
  • [31] New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus
    Bouza, E.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 : 44 - 52
  • [32] Methicillin-Resistant Staphylococcus aureus Diabetic Foot Crossed Infection: A Case Report
    Reina-Bueno, Maria
    Palomo-Toucedo, Inmaculada C.
    Castro-Mendez, Aurora
    Dominguez-Maldonado, Gabriel
    del Carmen Vazquez-Bautista, Maria
    PATHOGENS, 2020, 9 (07): : 1 - 9
  • [33] Virulence genes profile and biofilm formation of Methicillin-resistant and Methicillin-susceptible Staphylococcus aureus isolates from diabetic foot infections
    Ali, Sahd
    Ertugrul, Mustafa Bulent
    Bozdogan, Bulent
    MALAYSIAN JOURNAL OF MICROBIOLOGY, 2021, 17 (04) : 369 - 379
  • [34] Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in Latin America
    Luna, Carlos M.
    Rodriguez-Noriega, Eduardo
    Bavestrello, Luis
    Gotuzzo, Eduardo
    REVISTA CHILENA DE INFECTOLOGIA, 2010, 27 : S94 - S103
  • [35] Is It Time to Replace Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections?
    van Hal, Sebastiaan J.
    Fowler, Vance G., Jr.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (12) : 1779 - 1788
  • [36] Antimicrobial prescribing for treatment of serious infections caused by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in pediatrics: an expert review
    Avedissian, Sean N.
    Rhodes, Nathanial J.
    Shaffer, Christopher L.
    Tran, Lan
    Bradley, John S.
    Le, Jennifer
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (09) : 1107 - 1116
  • [37] Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus
    Ray, G. Thomas
    Suaya, Jose A.
    Baxter, Roger
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2013, 76 (01) : 24 - 30
  • [38] Infections with methicillin-resistant Staphylococcus aureus. Prevention and control
    Dresbach, T.
    Mueller, A.
    Simon, A.
    MONATSSCHRIFT KINDERHEILKUNDE, 2015, 163 (05) : 437 - 447
  • [39] Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections
    Loffler, Cindy A.
    MacDougo, Conan
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (06) : 961 - 981
  • [40] New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections
    Burke, Stuart L.
    Rose, Warren E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (04) : 483 - 491